KeyBanc analyst Paul Knight initiated coverage of Gerresheimer with an Overweight rating and EUR 200 price target. Gerresheimer’s leadership position in therapeutic delivery technology is not reflected in its 60% discount to peers like Stevanato and West Pharmaceutical, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GRRMF:
